Product Description
Mechanisms of Action: IAV Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sarepta
Company Location: CAMBRIDGE MA 02142
Company CEO: Douglas S. Ingram
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
13-I-0029 | P1 |
Completed |
Influenza, Human |
2016-06-29 |
|
7100-us-101 | P1 |
Terminated |
Influenza, Human |
2011-08-01 |